Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Shareholder Meeting (April 2018)
13 slides from Bristol-myers Squibb's shareholder meeting presentation, Apr 23, 2018
Slide 1: Bristol-Myers Squibb combines the agility of a biotech with the resources of a large pharma
2 Bristol-Myers Squibb combines the agility of a biotech company with the resources and stability of a large pharmaceutical company Delivered 8 new products in past 5 years 15 major market approvals in 2017 Our research and development pipeline supports our strong presence in key therapeutic areas O
Slide 2: 2017 Highlights
3 2017 Highlights 3 We have achieved significant growth across key product portfolios, building on the strategic foundation established by our transformation to a diversified specialty biopharmaceutical company Revenues of Prioritized Brands (millions) Total revenues increased 7%* +31% +9% Continued
Slide 3: Immuno-Oncology and Pipeline Update
Immuno-Oncology and Pipeline Update 2017 Update: Opdivo gained four additional FDA approvals for treatment of liver cancer, bladder cancer, colorectal cancer and adjuvant melanoma, two European approvals for treatment of bladder and head and neck cancer, and two Japan approvals for gastric cancer an
Slide 4: Board Refreshment
Board Refreshment 5 The Board elected Dr. Karen Vousden and Dr. José Baselga to the Board, effective January 1, 2018 and March 1, 2018, respectively Since January 2017, BMS has added a total of five new independent Directors New directors bring fresh perspectives and important skills and experience
Slide 5: Board Well Positioned to Support Company Strategy
Giovanni Caforio, M.D. 17 years of experience at Bristol-Myers Squibb, including previous role as COO Board Well Positioned to Support Company Strategy José Baselga, M.D., Ph.D. Physician-in-Chief, Memorial Sloan-Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College Commit
Slide 6: Committed to Sound Corporate Governance
Committed to Sound Corporate Governance Proxy access shareholder right Ability to call special meetings (25%) Extensive related party transaction policies and procedures No supermajority voting provisions for common stockholders No stockholder rights plan Semi-annual political contributions disclosu
Slide 7: Executive Compensation Supporting our Strategy
Executive Compensation Supporting our Strategy 8 Continued Commitment to our Compensation Philosophy and Structure Pay for Performance A substantial proportion of our executives’ pay is variable, at-risk based on our financial and operational results and delivered in the form of equity, supporting a
Slide 8: Executive Compensation
Executive Compensation 9 Broad changes became effective in 2016 that further enhanced the structural alignment between our incentive program and our strategy and directly reflected shareholder feedback Lengthened the performance period in our Performance Share Unit (PSU) program from one year to thr
Slide 9: We Value Your Support at Our 2018 Annual Meeting
We Value Your Support at Our 2018 Annual Meeting 10 10 2018 Bristol Myers-Squibb Board Recommendations Shareholder proposal on annual report disclosing how risks related to public concern over drug pricing strategies are incorporated into incentive compensation plans The request to report annually o
Slide 10: Forward-Looking and Non-GAAP Information
Forward-Looking and Non-GAAP Information This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ ma
Slide 11: Forward-Looking and Non-GAAP Information
Forward-Looking and Non-GAAP Information This presentation contains statements about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ ma
Slide 12: 2017 Compensation Plan Structure
Rewards creation of incremental shareholder value Provides a mix of short, medium and long-term performance periods Multi-year vesting helps to promote retention while maintaining pay-for-performance link 2017 Compensation Plan Structure Base Salary Annual Incentive (Paid in cash) Long-Term Incentiv
Slide 13: 2017 Compensation Plan Structure
2017 Compensation Plan Structure Bace ‘+ Allows us to attract and retain talent ina highly competi labor market i + Based on specialized qualifications, experience and role impact, and pay levels of comparable positions within peer group Salary ‘+ Salary increases based on competitive market, indivi
Bristol-Myers Squibb — Shareholder Meeting (April 2018) on 6ix